This comparison enhances understanding of the role of ACE2 in the pathophysiology of AKI and could inform therapeutic strategies such as targeting of ACE2 with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) to mitigate AKI in COVID-19. The gene discussed is ACE2; the disease is acute kidney injury.